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Background: Epithelial neutrophil-activating peptide 78 (ENA-78) and interferon g-
inducible protein 10 (IP10) belong to the CXC chemokine family and are considered
to be important factors in idiopathic pulmonary fibrosis (IPF). Idiopathic nonspecific
interstitial pneumonia (NSIP) and IPF are the two largest subsets of idiopathic
interstitial pneumonias (IIP). In patients with NSIP, the prognosis is generally good
compared with IPF. Therefore, the pathogenesis of NSIP seems to be different from
that of IPF, but this remains unclear. The aim of the present study was to evaluate
the contribution of ENA-78 and IP10 in the two diseases.
Methods: We measured the levels of ENA-78 and IP10 in serum and bronchoalveolar
lavage fluid (BALF) of patients with IPF (n ¼ 17), idiopathic NSIP (n ¼ 10) and healthy
subjects (n ¼ 12) by enzyme-linked immunosorbent assays.
Results: The level of ENA-78 in BALF was significantly higher in IPF patients than in
NSIP patients and controls. Serum levels of ENA-78 and BALF levels of IP10 in NSIP
patients were significantly higher than in patients with IPF and controls. In BALF of
patients with NSIP, IP10 level significantly correlated with the absolute number of
lymphocytes. In IPF patients, BALF IP10 levels also correlated with the proportion of
lymphocytes in BALF.
Conclusion: Our results show distinct profiles of CXC chemokines in IPF and NSIP, and
suggest that these chemokines play an important role in inflammatory cell
recruitment into the lung in patients with IIP.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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The classification of idiopathic interstitial pneumo-
nia (IIP) includes seven clinico-radiologic-patholo-
gical entities. Idiopathic pulmonary fibrosis (IPF)
and nonspecific interstitial pneumonia (NSIP) are
the two largest subsets of IIP.1–3 NSIP is distin-
guished from IPF by the temporal uniformity of
interstitial inflammation and/or fibrosis on histol-
ogy.1–3 The distinction between NSIP and IPF is
important for clinical decision-making because the
prognosis is generally good and the response to
corticosteroids and immunosuppressants is also
good in patients with NSIP compared with IPF.1–3
It is well known that NSIP is associated with relative
lymphocytosis with a predominance of CD8+ cells in
bronchoalveolar lavage fluid (BALF) compared with
IPF.4–6 Previous studies demonstrated that lympho-
cytosis correlated with the levels of interleukin
(IL)-6 in BALF of patients with NSIP.5 These results
suggest that the pathogenesis of NSIP is different
from that of IPF, though their mechanisms remain
elusive.
Chemokines are important for leukocyte re-
cruitment to the inflamed tissue. Chemokines
are divided into four subfamilies depending on
the position of the conserved cysteine resi-
dues (CXC, CC, C and CX3C).
7 It is well known
that the CC chemokines such as monocyte che-
moattractant protein 1 (MCP-1), macrophage in-
flammatory protein-1alpha (MIP-1a), and regulated
upon activation, normal T cell expressed and
secreted (RANTES), are closely related to the
expression of adhesion molecules and the mi-
gration of inflammatory cells into the lung.
There is sufficient evidence for the importance
of these chemokines in IPF.8–12 These CC chemo-
kines are also important in inflammatory cell
recruitment to the lung in idiopathic NSIP.13 The
CXC chemokines such as epithelial neutrophil-
activating peptide (ENA)-78, interferon g-inducible
protein (IP)10 and IL-8 are also important factors in
IPF.14,15 However, to our knowledge, there are no
reports demonstrating the role of the CXC chemo-
kine in idiopathic NSIP. We hypothesized that these
CXC chemokines mediate the recruitment of
inflammatory cells into the lung in patients with
NSIP as well, similar to the behavior of the CC
chemokine.
In the present study, we measured the concen-
trations of ENA-78 and IP-10 in BALF and serum
samples obtained from patients with IPF and
idiopathic NSIP to evaluate the contribution of
these chemokines, and to determine whether there
is a distinct profile of these factors in these
diseases.Materials and methods
Study population
The 39 subjects of this study were patients and
healthy volunteers enrolled in the Hospitals of
Nagasaki University School of Medicine. They
included 17 patients with idiopathic IPF (14 males
and 3 females, consisting of 5 current smokers, 3
ex-smokers and 9 nonsmokers, age; 61 10 years,
mean7SD;), 10 with idiopathic NSIP (5 males and 5
females, consisting of one current smoker, 2 ex-
smokers and 7 nonsmokers, age; 56 13 years),
and 12 healthy volunteers (8 males and 4 females,
12 nonsmokers, age; 24 5 years). None of the
enrolled patients had received steroid and other
immunosuppressive therapy at the time of clinical
sample collection. Patients with cancer in any
organ and those suspected to have malignancy
were excluded from the study. The diagnosis was
pathologically confirmed using surgical lung biopsy
specimens obtained in at least two different sites in
all patients. The patients with usual interstitial
pneumonia (UIP) and NSIP associated with collagen
vascular diseases were excluded in this study. In all
of 10 NSIP cases, the diagnosis was pathologically
confirmed as fibrotic NSIP, consisting of 5 Group II
and 5 Group III.16 In these NSIP patients, the
following high-resolution computed tomography
(HRCT) criteria were used: (1) predominantly
basal/subpleural distribution, (2) a mixture of
reticular and ground-glass abnormalities, with
traction bronchiectasis when ground-glass attenua-
tion was prominent, (3) the absence of consolida-
tion or nodules. All patients with NSIP fulfilled
these criteria. There were no significant differ-
ences in the mean %VC, FEV1%, %DLCO, PaO2 and
PaCO2 between IPF and NSIP. All healthy volunteers
had normal chest radiographs, were free of
symptoms and not taking any medications. The
study protocol was approved by the Human Ethics
Review Committees of Nagasaki University School
of Medicine and a signed consent form was
obtained from each subject.Bronchoalveolar lavage and blood sampling
With informed consent, BAL was performed as
described previously6,13,17 using a flexible fiberop-
tic bronchoscope (Olympus, P-20 Olympus, Tokyo,
Japan). Briefly, the bronchoscope was wedged into
one of the segmental or subsegmental bronchi of
the right middle lobe. Then, 50ml of sterilized
saline at body temperature was instilled through
the bronchoscope. The fluid was immediately
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and the procedure was repeated three times. BALF
was passed through two sheets of gauze and then
centrifuged at 500g for 10min at 4 1C. After
washing twice with calcium- and magnesium-free
phosphate-buffered saline (PBS, Gibco, UK), the
remaining cells were suspended in PBS supplemen-
ted with 10% heat-inactivated foetal calf serum and
were counted using a hemocytometer. An aliquot
was then diluted to a concentration of 2
105 cells=ml; and a 0.2ml cell suspension was spun
down onto a glass slide at 1100 rpm for 2min using a
Cytospin 2 cytocentrifuge (Shandon Instruments,
Sewickley, PA). The remaining fluid was centrifuged
at 500g for 5min, and supernatant was stored at
80 1C until examined. The slides were dried,
fixed, and then stained using the May–Giemsa
method. More than 200 cells were identified using
a photomicroscope. Subsets of lymphocytes in BALF
were examined by direct immunofluorescence
staining using fluorescein isothiocyanate-labeled
murine monoclonal anti-CD3, CD4 and CD8 anti-
bodies (Becton Dickinson, Mountain View, CA). The
stained cells were analyzed on a flow cytometer
(FACScan; Becton Dickinson, FACS Division). Blood
for determination of ENA-78 and IP10 in serum was
obtained from the patients at the same time.
Serum was frozen at 80 1C until analysis.Measurement of ENA-78 and IP10
The concentrations of ENA-78 and IP10 in serum
and BALF were measured by commercially available
enzyme-linked immunosorbent assay kits (Quanti-
kine; R&D systems, Minneapolis, MN) according to
the protocols provided by the manufacturer. The
detection limits were 15 and 1.67 pg/ml for ENA-78
and IP10, respectively. Although BAL proceduresTable 1 Total and differential cell counts in BALF.
Healthy volunteers
Total cell counts (105=ml) 1.1 (0.4)
Macrophages (%) 86.9 (7.3)
Lymphocytes (%) 10.8 (6.7)
Neutrophils (%) 1.9 (4.1)
Eosinophils (%) 0.4 (0.9)
Lymphocyte subsets
CD3 (%) 79.8 (6.3)
CD4 (%) 33.9 (11.5)
CD8 (%) 45.0 (11.0)
CD4/CD8 0.9 (0.5)
Data are mean (SD).aPo0.01 compared with normal subjects; bPo
IPF.generally have a dilutional effect on the recovery
of chemokines, a good correlation was observed
between the original values and standardized
values by albumin concentrations in BALF (data
not shown). Thus, the original values of chemokine
concentrations were reported in this study rather
than corrected values by albumin concentrations.
Statistical analysis
Data was expressed as mean7standard deviation of
the mean (SD). Differences between groups were
examined using one-way analysis of variance. The
post-hoc test used was Fisher’s PLSD test. We also
used Spearman’s rank correlation analysis to
examine the relationship between two variables.
Statistical analysis was performed using StatView-J
5.0 software (Abacus Concepts, Berkeley, CA). A P-
valueo0:05 denoted the presence of a statistically
significant difference.Results
BALF differential cell count
Table 1 shows the total and differential cell counts
in BALF of the three groups. Cell recovery in
patients with IPF and idiopathic NSIP was signifi-
cantly higher than in normal controls (Po0:01). The
percentage of alveolar macrophages in patients
with NSIP was significantly lower than in patients
with IPF and controls (Po0:01), and those in
patients with IPF were also significantly lower than
in the controls (Po0:05). On the other hand, the
percentage of lymphocytes in patients with NSIP
was significantly higher than in patients with IPF
and controls (Po0:01). No significant differences(n ¼ 12) NSIP (n ¼ 10) IPF (n ¼ 17)
3.3 (1.1)a 4.1 (1.6)a
55.2 (20.2)a,c 74.9 (13.1)b
39.9 (18.6)a,c 14.8 (10.7)
2.8 (2.5) 5.3 (5.3)
2.1 (1.7) 4.9 (8.1)
83.1 (16.9) 85.7 (15.1)
24.0 (9.8)c 48.2 (20.3)b
60.1 (18.1)b,c 35.4 (15.9)
0.4 (0.3)c 1.8 (1.5)
0.05 compared with normal subjects; cPo0.01 compared with
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and eosinophils among the three groups. The CD4/
CD8 ratio in patients with NSIP was significantly
lower than in patients with IPF.0
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(A)BALF and serum concentrations of ENA-78
and IP10
As shown in Figs. 1 and 2, BALF concentrations of
ENA-78 in patients with IPF (79:5 70:5 p=ml) were
higher than in the control (5:9 10:0 pg=ml;
Po0:001) and patients with NSIP (25:1
13:6 pg=ml; Po0:01), but the serum concentrations
of ENA-78 in patients with NSIP (3420:7
3298:8 pg=ml) were higher than those in the control
(1099:6 580:0pg=ml; Po0:02) and patients with
IPF (1267:1 1148:2pg=ml; Po0:02). The concen-
trations of IP10 were elevated in BALF of patients
with NSIP (207:7 122:7 p=ml) compared with the
control (29:5 25:0 pg=ml; Po0:0001) and patients
with IPF (87:7 99:2pg=ml; Po0:01). As shown in
Fig. 2, the concentrations of IP10 in serum in0
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Figure 1 Box plots of ENA-78 (A) and IP10 (B) concentra-
tions in bronchoalveolar lavage fluid (BALF) of patients
with idiopathic pulmonary fibrosis (IPF), idiopathic
nonspecific interstitial pneumonia (NSIP), and control
subjects.
Healthy
volunteers
NSIP IPF
(B)
Figure 2 Box plots of ENA-78 (A) and IP10 (B) concentra-
tions in serum of patients with IPF, idiopathic NSIP, and
control subjects.patients with NSIP (423:3 384:0 p=ml) were higher
than in the control (77:9 29:3pg=ml; Po0:01).Correlations between chemokine
concentrations and clinical data
ENA-78 and IP10 are chemotactic factors for
inflammatory cells. Accordingly, we examined in
paired samples the correlation between these
chemokines and BALF cell proportions. Data of all
subjects (n ¼ 39) showed that the total cell
number, the absolute numbers of macrophages,
lymphocytes and neutrophils, and the percentages
of neutrophils correlated significantly with BALF
concentrations of ENA-78 (Table 2). The concentra-
tions of IP10 also correlated significantly with the
total cell number, the percentages of macrophages,
lymphocytes and neutrophils, and the absolute
number of lymphocytes and neutrophils in BALF of
all subjects (Table 2). In patients with NSIP, the
concentrations of IP10 correlated inversely with
the percentages of macrophages and correlated
significantly with the absolute number of lympho-
cytes in BALF (Table 2). In BALF obtained from
patients with IPF, the concentrations of IP10
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Table 2 Correlation between chemokine levels and BAL findings.
Overall (n ¼ 39) NSIP (n ¼ 10) IPF (n ¼ 17)
ENA-78 IP10 ENA-78 IP10 ENA-78 IP10
Total cell counts 0.713a 0.487a 0.043 0.164 0.382 0.137
Macrophages (%) 0.214 0.785a 0.073 0.721b 0.079 0.419
(absolute number) (0.715a) (0.202) (0.031) (0.335) (0.245) (0.398)
Lymphocytes (%) 0.020 0.811a 0.024 0.636 0.165 0.731a
(absolute number) (0.430a) (0.903a) (0.207) (0.697b) (0.015) (0.766a)
Neutrophils (%) 0.431a 0.327b 0.383 0.261 0.178 0.197
(absolute number) (0.603a) (0.407b) (0.383) (0.248) (0.235) (0.194)
Data are correlation coefficient.ao0.01; bo0.05.
ENA-78 and IP10 in IPF and NSIP 1149correlated with the percentage and the number of
lymphocytes (Table 2). There was no significant
correlation between serum and BALF concentra-
tions of ENA-78 in all subjects, while the BALF
concentrations of IP10 correlated with the serum
concentrations of IP10 (r ¼ 0:568; Po0:01). BALF
and serum concentrations of ENA-78 and IP10 did
not correlate with any pulmonary function tests
including PaO2, VC, %VC, FEV1, %FEV1, or %DLCO in
patients with IPF or NSIP with the exception that
there was significant correlation between serum
concentrations of ENA-78 and FEV1 in patients with
NSIP (r ¼ 0:821; Po0:05). The levels of C-reactive
protein (CRP) in serum of almost all cases were
within normal range and there was no significant
correlation between the CRP levels and the
chemokine levels in BALF and serum in the
different groups of patients (data not shown).Discussion
The major finding of the present study was that
patients with IPF showed elevated concentrations
of ENA-78 in BALF compared with the control
subjects and patients with idiopathic NSIP. Inver-
sely, elevated IP10 BALF concentrations were
observed in patients with NSIP compared with the
control subjects and patients with IPF. On the other
hand, the serum concentrations of ENA-78 and IP-
10 were higher in NSIP patients than in the control,
although those in IPF patients were similar to those
of the control. The concentrations of IP10 in BALF
correlated with the percentage and number of
lymphocytes in BALF of IPF patients and also
correlated with the absolute number of lympho-
cytes in BALF of NSIP patients.One of the distinct clinical features of NSIP is the
better prognosis than that of IPF. It is therefore
important to clarify the differences in the patho-
genesis between IPF and idiopathic NSIP. The
significant contribution of the CC chemokines such
as RANTES and MCP-1 has already been reported in
the pathogenesis of IPF and idiopathic NSIP.8–13 In
addition, our previous study showed that the
concentrations of RANTES in BALF were significantly
higher in patients with NSIP compared with controls
and patients with IPF, suggesting a different profile
of the CC chemokines between NSIP and IPF. The
CXC chemokines such as ENA-78 and IP10 are also
major inflammatory cell attractants in IPF and NSIP.
Here, we demonstrated distinct profiles of ENA-78
and IP10 between IPF and NSIP.
The CXC subfamily can be divided into two
subgroups depending on the presence or absence
of the Glu-Leu-Arg (ELR) motif, which immediately
precedes the first cysteine residue (ELR+CXC and
ELRCXC chemokines, respectively). ENA-78 is a
potent ELR+CXC chemokine and known to selec-
tively attract and activate neutrophils. ENA-78 was
initially identified from the conditioned medium of
a human type II epithelial cell line A549.18
Subsequent studies showed that it is produced by
other tissue cells, including monocytes and en-
dothelial cells.19,20 Increased ENA-78 expression
has been shown in other inflammatory and infec-
tious diseases such as rheumatoid arthritis,21
bacterial meningitis,22 IPF1 and acute respiratory
distress syndrome (ARDS).23,24 In the latter condi-
tion, high concentrations of ENA-78 and IL-8 were
detected in BALF and they correlated significantly
with the numbers of neutrophils in BALF.23 Keane
and colleagues15 demonstrated that lung tissues
from the patients with IPF also constitutively
express more ENA-78 than control lung tissues.
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findings. There were no significant correlations
between BALF concentrations of ENA-78 and the
percentage and number of neutrophils in BALF of
IPF and NSIP patients while a significant correlation
was observed in all subjects. These findings suggest
that ENA-78 is not the predominant neutrophil
chemoattractant in IPF and NSIP while this study
used relatively small numbers of patients.
IP10 is a potent ELRCXC chemokine known to
induce chemotaxis of lymphocytes, especially
activated T cells.25 IP10 is induced in monocytes/
macrophages by interferon-g: IP10 is an important
mediator for the recruitment of activated lympho-
cytes into the lungs in certain pulmonary diseases
such as sarcoidosis,26 tuberculosis27 and HIV-asso-
ciated T cell alveolitis.28 In sarcoidosis, IP10 is
strongly expressed in sarcoid tissues and there are
positive correlations between BALF concentrations
of IP10, the degree of CD4 alveolitis, the expression
of Th1 cytokines and CXCR3 (CXC chemokine-
specific receptor) by sarcoid T cells.26 These results
suggest a role for IP10 in the mechanisms that
account for sarcoid T cell activation and the
development of sarcoid granuloma. In HIV patients
with high intensity T cell alveolitis, lymphocytes
recovered from BALF were CD8+ T cells that
expressed high concentrations of CXCR3 and IFN-g;
a phenotype that is characteristic of Th1 cells.
These findings make IP10 an attractive candidate
for inflammatory cell attraction to the lung in IPF
and idiopathic NSIP. We found elevated IP-10 BALF
concentrations in patients with NSIP compared with
healthy controls and patients with IPF. On the other
hand, serum concentrations of IP-10 were higher in
NSIP patients than in the control. The concentra-
tions of IP10 in BALF also correlated with the
percentage and number of lymphocytes in BALF of
IPF patients and also correlated with the absolute
number of lymphocytes in BALF of NSIP patients.
Taken together, our results suggest that lympho-
cytes may play an important role in IPF develop-
ment and that IP10 contributes significantly to the
accumulation of lymphocytes in the lung of various
pulmonary inflammatory diseases, especially in
NSIP.
In the present study, the BALF concentrations of
ENA-78 were elevated in IPF patients compared
with the control subjects and patients with NSIP.
The elevated BALF ENA-78 concentrations may be
further evidence of the importance of angiogenesis
in the pathogenesis of pulmonary fibrosis. In fact,
the existence of neovascularization in IPF was
originally identified by Turner–Warwick, who ex-
amined the lungs of patients with widespread
interstitial pneumonia, and demonstrated neovas-cularization leading to anastomoses between the
systemic and pulmonary microvasculature and
evidence of extensive vascular remodelling in areas
of fibrosis.29 The CXC chemokines have been shown
to have disparate effects in mediating angiogenesis
as a function of the presence or absence of ELR
motif. ENA-78 and IL-8, both contain the ELR motif,
which confers potent angiogenic activity, whereas
members such as IP10, which lack the ELR motif,
inhibit angiogenesis. Keane and colleagues demon-
strated an imbalance of expression of angiogenic
(ENA-78 and IL-8) vs angiostatic (IP10) factors in
lung biopsy specimens from IPF patients.14,15
Angiogenesis plays an important role in wound
healing and may contribute to the fibropro-
liferation and extracellular matrix deposition ob-
served in IPF. Keane and colleagues also showed
that neutralization of macrophage inflammatory
protein 2 (MIP-2), a murine functional homolog of
IL-8, attenuates bleomycin-induced pulmonary fi-
brosis via inhibition of angiogenesis.30 In contrast,
administration of IP10 led to a reduction in
pulmonary fibrosis that was mediated through the
inhibition of angiogenesis.31 These findings suggest
that ENA-78 and IP10 may play important roles in
the pathogenesis of IPF through regulation of
angiogenic activity. The elevated BALF levels of
ENA-78 in IPF and IP10 in NSIP, respectively, which
were shown in the present study, therefore, may
affect directly the difference in the prognosis of
patients with these two diseases. However, to our
knowledge, there are no reports of the difference
in angiogenesis between IPF and NSIP. Further
studies on angiogenesis and vascular remodelling
are needed to clarify whether NSIP is pathogeneti-
cally different from IPF.
In conclusion, we demonstrated in the pre-
sent study the presence of elevated BALF concen-
trations of ENA-78 in IPF and IP10 in NSIP. The
findings suggest that ENA-78 may serve as an
angiogenic factor in IPF rather than a chemoat-
tractant, and that IP10 may act as a predo-
minant chemotactic factor for lymphocytes in
idiopathic NSIP.Acknowledgments
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